ライフサイエンスコーパス: testicular cancer

1 ne years (for chemotherapy to treat advanced testicular cancer).

2 lorectal, pancreas, ovary, kidney, lung, and testicular cancer).

3 as, cryptorchidism, hypospermatogenesis, and testicular cancer).

4 the recent clinically relevant literature on testicular cancer.

5 minimization of treatment in good-prognosis testicular cancer.

6 subtypes of acute myelogenous leukemia, and testicular cancer.

7 erative orchiopexy or orchiectomy to prevent testicular cancer.

8 all common tumour types except leukaemia and testicular cancer.

9 patients without microlithiasis, 38 (8%) had testicular cancer.

10 cceptable toxicity in patients with relapsed testicular cancer.

11 ents had histopathologic correlation; 13 had testicular cancer.

12 ed 500 twins with breast cancer and 194 with testicular cancer.

13 r was 37.5 (12.3-115.6) in twins of men with testicular cancer.

14 nts with breast cancer at young ages or with testicular cancer.

15 ders of the male reproductive tract, notably testicular cancer.

16 er childhood cancers, Hodgkin's disease, and testicular cancer.

17 ug reaction in adult patients with germ cell testicular cancer.

18 areness among clinicians treating metastatic testicular cancer.

19 per urinary tract, renal cell carcinoma, and testicular cancer.

20 7-27) for prostate cancer to 99% (96-99) for testicular cancer.

21 esophageal, laryngeal, Hodgkin lymphoma, and testicular cancer.

22 osely linked to cannabis use is non-seminoma testicular cancer.

23 e lowest uptake was found in lung cancer and testicular cancer.

24 vant issues in the biology and management of testicular cancer.

25 from 1.1% for pancreatic cancer to 98.2% for testicular cancer.

26 and from patients previously diagnosed with testicular cancer.

27 ys of cisplatin combination chemotherapy for testicular cancer.

28 e multidisciplinary management of metastatic testicular cancer.

29 ding disorders of sexual differentiation and testicular cancer.

30 d to determine the benefits of screening for testicular cancer.

31 h testicular microlithiasis will not develop testicular cancer.

32 h testicular microlithiasis will not develop testicular cancer.

33 yndrome, which may result in infertility and testicular cancer.

34 nized as late complications of treatment for testicular cancer.

35 will cure 70% of patients with disseminated testicular cancer.

36 med at improving quality of life in men with testicular cancer.

37 cancer including ovarian, kidney, lung, and testicular cancers.

38 ts had microlithiasis; 13 of these (27%) had testicular cancers.

39 genetic impairment of NER, such as skin and testicular cancers.

40 identified in non-PJS patients with sporadic testicular cancers.

41 .19; 0.17-0.22), melanoma (0.34, 0.27-0.43), testicular cancer (0.47, 0.33-0.67), and endometrial can

42 .6% aged 25-37 years, 57.4% 38-50 years, 88% testicular cancer, 10% lymphoma, matched for body mass i

43 (35.4 percent), lung cancer (22.5 percent), testicular cancer (14.4 percent), and lymphoma (12.8 per

44 Rs were highest for multiple myeloma (30.5), testicular cancer (17.0), and kidney cancer (12.5); for

45 al cancer, 20.2% (18.9-21.5) in survivors of testicular cancer, 26.6% (24.7-28.6) in female survivors

46 FE rate was greatest for testicular cancer (27.9%), then small-cell lung cancer (

47 ith microlithiasis) patients with a mass had testicular cancer, 43 (10 with microlithiasis) had benig

48 cal cancer, 18.9 (16.6-21.1) in survivors of testicular cancer, 55.7 (50.4-61.1) in female survivors

49 slightly higher lifetime mortality risk from testicular cancer (598 per 100 000; 95% uncertainty inte

50 in African Americans), far more common than testicular cancer (7:100,000).

51 owever, life expectancy loss attributable to testicular cancer (83 days; 95% UI: 42, 124) was more th

52 Anecdotal reports of men developing testicular cancer after previous identification of micro

53 r, and new developments in the management of testicular cancer aimed at improving quality of life in

54 include a worldwide increasing incidence in testicular cancer among young men and alterations in twi

55 inumab and no deaths and one case of cancer (testicular cancer) among 319 patients who received place

56 er and other biliary cancer, ovarian cancer, testicular cancer, anal cancer in male individuals, and

57 Testicular cancer and infertility affect a similar age g

58 ancers without an apparent age gradient were testicular cancer and mesothelioma.

59 Of 13 patients with testicular cancer and paraneoplastic limbic or brain-ste

60 e fractures, poor sperm quality, and perhaps testicular cancer and rheumatoid arthritis) may yield sp

61 ar with the available treatment regimens for testicular cancer and their associated toxic effects.

62 were more likely to have tumours other than testicular cancer and to develop ataxia, and had a worse

63 e been linked to risk of childhood leukemia, testicular cancer, and breast cancer in the offspring.

64 long-term survivors of cervical, breast, and testicular cancer, and Hodgkin lymphoma provides an evid

65 survivors of breast cancer, cervical cancer, testicular cancer, and Hodgkin lymphoma.

66 literature on links between infertility and testicular cancer, and new developments in the managemen

67 17 years or older, diagnosed with germ cell testicular cancer, and previously treated with cisplatin

68 ommon mechanisms involved in infertility and testicular cancer, and scientifically driven evidence-ba

69 and placenta, as well as in prostate cancer, testicular cancer, and uterine cancer.

70 ent of male contraceptives, the treatment of testicular cancers, and ultimately for tissue regenerati

71 er; 487518 due to liver cancer; 13927 due to testicular cancer; and 829396 due to non-Hodgkin lymphom

72 ommon conditions known to be associated with testicular cancer are cryptorchidism, infertility, and o

73 itation and rehabilitation interventions for testicular cancer are safe and efficacious, and should b

74 The major pathological types of testicular cancer are seminoma and non-seminomatous germ

75 Between 90% and 95% of testicular cancers are germ cell tumors (GCTs).

76 ithiasis is highly associated with confirmed testicular cancer, as well as with US evidence of testic

77 based treatment recommendations for advanced testicular cancer based on risk stratification.

78 out the management of early non-seminomatous testicular cancer because survival is almost 100% irresp

79 the 11th birthday on three men who developed testicular cancer but, in each, the procedure failed.

80 e stage 4 non-small cell lung cancer and one testicular cancer), but these were judged unrelated to t

81 hat the action of Dnd1Ter was not limited to testicular cancer, but also significantly increased poly

82 in is one of the primary drugs used to treat testicular cancer, but the incidence of significant pulm

83 yptorchism is an established risk factor for testicular cancer, but the role of age at surgical corre

84 cases, 26% of lung cancer cases, and 47% of testicular cancer cases.

85 In the testicular cancer cell line, NT2, we previously demonstr

86 Ts; (b) elevated expression of Ape1/ref-1 in testicular cancer cell lines results in resistance to ce

87 Re-expression of miR-199a in testicular cancer cells led to suppression of cell growt

88 atin toxicity and reactive oxygen species in testicular cancer cells.

89 The international Testicular Cancer Consortium (TECAC) combined five publi

90 In this study, the international Testicular Cancer Consortium assemble 10,156 and 179,683

91 bacute limbic and brain-stem dysfunction and testicular cancer contains antibodies against a protein

92 of 5190 men with GCC who entered the Danish Testicular Cancer database between January 1, 1984, and

93 prospectively maintained Indiana University testicular cancer database was queried for patients with

94 From the Danish Testicular Cancer database, we identified all patients w

95 Clinical data were extracted from the Danish Testicular Cancer database.

96 18 were identified in the prospective Danish Testicular Cancer database.

97 Testicular cancer deaths also occurred less frequently t

98 ly curable with cisplatin-based therapy, and testicular cancer-derived human embryonal carcinoma (EC)

99 mon diseases, including male infertility and testicular cancer, due to abnormalities in SSC function.

100 Permanente members, who were diagnosed with testicular cancer during 1973-1996 and who were 15 years

101 Participants were followed for incident testicular cancer during their service.

102 2 Diabetes, Breast Cancer, Prostate Cancer, Testicular Cancer, Gallstones, Glaucoma, Gout, Atrial Fi

103 rs include cryptorchidism, family history of testicular cancer, gonadal dysgenesis, infertility, cann

104 we show that fine-mapping of pancreatic and testicular cancer GWAS within one of these loci (Region

105 hile lymphoma, bladder cancer, melanoma, and testicular cancer had lower-than-average ratios.

106 Patients with testicular cancer had the highest sperm retrieval rates

107 Testicular cancer has become a model for a curable neopl

108 g the diagnosis, treatment, and prognosis of testicular cancer have been reported.

109 The aetiologies of breast and testicular cancers have genetic components, for breast c

110 s were positively associated with kidney and testicular cancer [hazard ratio (HR) = 1.10; 95% CI: 0.9

111 30 years from diagnosis of cervical cancer, testicular cancer, Hodgkin lymphoma in women, breast can

112 nd 1.58 (linear trend test p = 0.18) and for testicular cancer, HRs were 1.0, 1.04, 1.91, 3.17 (linea

113 We analysed risks of breast and testicular cancer in dizygotic twins compared with monoz

114 ages younger than 45 years and with incident testicular cancer in England and Wales during 1971-89 by

115 train 129 males recapitulate many aspects of testicular cancer in human infants and can be used to ev

116 PFOA exposure was associated with kidney and testicular cancer in this population.

117 While the incidence rate of testicular cancer in US White males ages 15-64 years did

118 lar germ cell tumors (TGCT), the most common testicular cancer in young men.

119 In response to a report that testicular cancer incidence in non-Hispanic White males

120 s performed to determine the relationship of testicular cancer, intratesticular mass, and microlithia

121 The mean age at diagnosis for testicular cancer is 33 years.

122 Testicular cancer is a curable cancer.

123 The most common presenting symptom of testicular cancer is a painless testicular mass.

124 udies suggest that an increased incidence of testicular cancer is due to a birth-cohort effect and se

125 Testicular cancer is highly curable with cisplatin-based

126 Although testicular cancer is highly treatable and curable, there

127 in semen quality and increased incidence of testicular cancer is hypothesised to be associated with

128 with low-risk disease is acceptable because testicular cancer is still curable if metastatic recurre

129 t referral to a urologist are indicated when testicular cancer is suspected.

130 Testicular cancer is the first solid tumor with a remark

131 Testicular cancer is the most common malignancy in males

132 Testicular cancer is the most common solid malignancy am

133 Testicular cancer is the most common solid malignancy in

134 Testicular cancer is the most common solid tumor diagnos

135 Testicular cancer is the most common type of cancer in m

136 in 2004 that screening asymptomatic men for testicular cancer is unlikely to produce additional bene

137 ecent advances in diagnosis and treatment of testicular cancer, its causes remain unknown.

138 Children and adolescents with testicular cancer, leukaemia, and Ewing sarcomas are at

139 hormone milieu, leading to the induction of testicular cancer (Leydig cell tumors).

140 Male survivors of testicular cancer, lymphoma, and leukaemia aged 25-50 ye

141 elevated Ape1/ref-1 levels observed in human testicular cancer may be related to their relative resis

142 Aetiology of breast and testicular cancers may have prenatal factors, possibly e

143 nical stage (CS) I nonseminomatous germ cell testicular cancer (NSGCT).

144 11th birthday were not at increased risk of testicular cancer (odds ratio = 0.6, 95% CI: 0.08, 5.4).

145 erm cell tumors (GCTs) from 10 patients with testicular cancer of various histologies including semin

146 ober 2007) was also searched using the terms testicular cancer or germ cell tumors.

147 must be maintained, as defects can result in testicular cancer or infertility.

148 resence of cardiovascular disease, diabetes, testicular cancer, or prostate cancer.

149 diagnosis and had lymphoma, acute leukemia, testicular cancer, ovarian cancer, or female breast canc

150 The increase in IPC rates for metastatic testicular cancer patients receiving CCT indicates a nee

151 tabase, we tabulated IPC rates in metastatic testicular cancer patients receiving CCT, namely invasiv

152 t increase in rates of IPC use in metastatic testicular cancer patients receiving CCT, rising from 5

153 npatient palliative care (IPC) in metastatic testicular cancer patients receiving critical care thera

154 and 2019, the rates of IPC among metastatic testicular cancer patients undergoing CCT increased from

155 Of 420 metastatic testicular cancer patients undergoing CCT, 70 (17%) rece

156 Approximately 50% of these testicular cancer patients will subsequently be cured wi

157 cisplatin-induced ototoxic effects in adult testicular cancer patients.

158 treatment regimen cures 90-95% of metastatic testicular cancer patients.

159 For patients diagnosed with early-stage testicular cancer radical orchidectomy is the primary th

160 All 209 new patients with testicular cancer referred between June 1992 and May 199

161 Testicular cancer remains a major success story in the r

162 Two genome-wide association studies for testicular cancer report associations at three new loci,

163 Testicular cancer research continues to modify current t

164 Testicular cancers respond favorably to chemotherapy wit

165 , Nanog and Ccnd1, genes with known roles in testicular cancer risk and tumorigenesis, respectively,

166 ssociation of a history of cryptorchism with testicular cancer risk was 4.8 (95% confidence interval

167 These findings do not support routine testicular cancer screening in this population.

168 her than English on the benefits or harms of testicular cancer screening.

169 xercise and psychological support within the testicular cancer space, patients and caregivers, highli

170 , 30 vulvar, 24 ovarian, 20 cervical, and 30 testicular cancer specimens from patients from the Unite

171 solve, with much reliance on using data from testicular cancer studies.

172 nnecessary evaluations, and low incidence of testicular cancer suggest that routine screening of asym

173 is a longitudinal study of cisplatin-treated testicular cancer survivors (TCS) enrolled from 2012 to

174 rmation on adverse health outcomes (AHOs) in testicular cancer survivors (TCSs) after four cycles of

175 s are an important complication that affects testicular cancer survivors as a consequence of treatmen

176 Testicular cancer survivors have high rates of metabolic

177 Health-related issues that confront testicular cancer survivors include the late medical eff

178 Testicular cancer survivors may experience mental illnes

179 Testicular cancer survivors use mental health services m

180 Large databases on testicular cancer survivors were analyzed to further def

181 herapy can represent a significant burden to testicular cancer survivors.

182 y white men aged 18-55 years into a study of testicular cancer susceptibility conducted in the Philad

183 mors after older radiotherapy strategies for testicular cancer (TC) are well established.

184 ardiovascular disease (CVD) in patients with testicular cancer (TC) given chemotherapy in European st

185 Germ cell testicular cancer (TC) represents a malignancy with high

186 Testicular cancer (TC) survivors have an increased risk

187 Using complete information regarding testicular cancer (TC) treatment burden, this study aime

188 Testicular cancer (TC) treatment is clearly associated w

189 etachronous contralateral (second) germ cell testicular cancer (TC).

190 rtant adverse effects after chemotherapy for testicular cancer (TC).

191 tem encephalitis occurs more frequently with testicular cancer than with most other cancers.

192 of 184 consecutive patients with metastatic testicular cancer that had progressed after they receive

193 nd on the benefits or harms of screening for testicular cancer that would affect the USPSTF's previou

194 Despite a high cure rate in patients with testicular cancer, there remain patients in the poor pro

195 he adult-onset disorders low sperm count and testicular cancer, they can constitute a testicular dysg

196 Excellent response of testicular cancer to radiation and chemotherapy results

197 ection, ranging from <1/tumor in thyroid and testicular cancers to >10/tumor in endometrial and color

198 All incident cases of testicular cancer treated with orchiectomy in Ontario, C

199 widely accepted strategy in clinical stage I testicular cancer treatment in the community.

200 ere selected based on pertinence to advanced testicular cancer treatment, associated complications, a

201 carcinoma, men undergoing surveillance after testicular cancer treatment, parents of patients treated

202 wo), nasopharyngeal (one), thyroid (one) and testicular cancer (two).

203 ge 40 years in monozygotic twins of men with testicular cancer was 14% (4-46).

204 The relative risk of testicular cancer was 37.5 (12.3-115.6) in twins of men

205 In the early 1970s, metastatic testicular cancer was associated with only 5% survival.

206 The overall risk of testicular cancer was significantly higher in dizygotic

207 expansions underlie some cases of inherited testicular cancer, we also analyzed germline DNA from me

208 of a recent chemotherapy trial for advanced testicular cancer, we discuss the issues that investigat

209 In long-term survivors of testicular cancer, we observed a two-fold or greater ris

210 lel reports of regional differences in human testicular cancer, we postulate that this may reflect ch

211 y losses and lifetime mortality risks due to testicular cancer were compared with life expectancy los

212 2 603 person-years of follow-up, 43 cases of testicular cancer were identified (incidence rate: 3.67

213 Two thousand six hundred nineteen cases of testicular cancer were matched to 13,095 controls.

214 August 1992 to April 1998, 65 patients with testicular cancer were treated with high-dose carboplati

215 noma, thyroid cancer, pancreatic cancer, and testicular cancer) were identified among ABOi recipients

216 nsurgical cancers, principally lymphomas and testicular cancer, were few but consistently showed bett

217 on and management of a long-term survivor of testicular cancer who was previously treated with surger

218 5 patients with pathological stage II or III testicular cancer who were treated with platinum-based c

219 veloped to project outcomes in patients with testicular cancer who were undergoing CT surveillance in

220 nd surveillance of patients and survivors of testicular cancer, will continue to advance the field an

221 The largest AOR was for testicular cancer with the very high exposure category [

222 predisposing factor of male infertility and testicular cancer, yet the etiology remains largely unkn